Search - tctmd.com

Displaying 601 - 620 of 1422

Sort: Relevancy | Date

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

March 10, 2017

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

News Daily News

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

March 03, 2017

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

News Daily News

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

February 28, 2017

Ticagrelor May Be Useful for Secondary Prevention After Stroke, TIA If Initial Event Is Related to Atherosclerosis

News Conference News ISC 2017

Ticagrelor May Be Useful After Stroke, TIA if Event Related to Atherosclerosis

February 28, 2017

Triple Antiplatelet Therapy Does Not Reduce Recurrent Events in Patients With Acute Ischemic Stroke or TIA

News Conference News ISC 2017

Triple Antiplatelet Therapy Does Not Cut New Events in Acute Ischemic Stroke or TIA

February 23, 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

TCTMD’s Top 10 Most Popular Stories for January 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2017

February 01, 2017

US Data Show Positive Trends in Cardiovascular Care, Though Opportunities for Progress Persist

News Daily News

US Data Show Positive Trends in Cardiovascular Care, Though Opportunities for Progress Persist

Yael L. Maxwell

January 23, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

FDA’s Latest Move Against Aspirin for CVD Primary Prevention: A Picture Is Worth 11 Words

January 13, 2017

News Daily News

New TAVR Guidance Aims to Ease Evaluation, Management of Patients With Aortic Stenosis

January 05, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

December 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.